Depression is common, costly, debilitating, and associated with increased risk of suicide. It is
one of the leading global public health problems. Although existing available …

Replicated international studies have underscored the human and societal costs associated
with major depressive disorder. Despite the proven efficacy of monoamine-based …

Background In treatment-resistant depression, commonly defined as a lack of response to
two or more consecutive treatments during the current depressive episode, the percentage …

Background Ketamine appears to have a therapeutic role in certain mental disorders, most
notably depression. However, the comparative performance of different formulations of …

This manuscript reviews the clinical evidence regarding single-dose intravenous (IV)
administration of the novel glutamatergic modulator racemic (R, S)-ketamine (hereafter …

Objective: Ketamine may reduce suicidal ideation in treatment-resistant depression. But it is
not known how quickly this occurs and how long it persists. We undertook a systematic …

Late-life depression occurring in older adults is common, recurrent, and malignant. It is
characterized by affective symptoms, but also cognitive decline, medical comorbidity, and …

Therapeutic claims about many psychedelic drugs have not been evaluated in any studies
of even modest rigor. The science of psychedelic drugs is strengthening however, making it …

Patients with treatment-resistant depression (TRD) have higher rates of relapse and
pronounced decreases in daily functioning and health-related quality of life compared to …

Background Intranasal esketamine has received regulatory approvals for the treatment of
depression. Recently a large trial of repeated dose racemic ketamine also demonstrated …